Furthermore, the effects of TACC3 overexpression on DFS were consistent among different tumor types: hepatocellular carcinoma (HR=3.03, 95% CI=2.06-4.44), gastric cancer (HR=2.29, 95% CI=1.38-3.82), colorectal cancer (HR=2.05, 95% CI=1.13-3.72), and prostate cancer(HR=3.03, 95% CI=1.79-5.00) (Figure 3). The gene discussed is TACC3; the disease is prostate carcinoma.